Skip to content
Research Article Open access CC BY 4.0

Therapeutic Advancement in Treatment and Prevention of Nipah Viral Infection: A Review

Mary K. Kallon, Daniel Maada Mami, Emmanuel Tom Mami, Mariam Romba, M. Patrick Andrew, M. Sylvester Martain

Asian Journal of Research in Infectious Diseases · pp. 51–65 · Published 29 Apr 2024

10.9734/ajrid/2024/v15i4343

Abstract

The Nipah virus (NiV) is an emerging zoonotic pathogen that poses a major risk to global health, with a high mortality rate and the potential for wide outbreaks. NiV, which originated in fruit bats, has shown a concerning potential to infect humans and cause serious respiratory and neurological disorders. The virus has a pleomorphic structure and a broad host range, preventing efforts to understand and regulate its pathogenesis. This review discusses current advances in the prevention and management of NiV, including the efficacy of several antiviral therapies in vitro and in vivo. Treatments such as Ribavirin, Favipiravir, Acyclovir, Remdesivir, and Balapiravir have produced varying results, whilst monoclonal antibodies such as m102.4, h5B3.1, and nAH1.3 provide effective neutralization but require additional testing in humans. In addition, innovative vaccination techniques such as recombinant measles virus, subunit vaccines, vector vaccines, and the novel mRNA-1215 vaccine have shown success in preclinical and early clinical trials. To reduce the risk of human transmission, preventive measures include early outbreak detection through improved surveillance systems, exposure-based screening, and educational activities. This covers vital guidelines like avoiding raw date palm sap during outbreak seasons and using physical barriers to prevent bat-to-human transmission, which is vital for controlling this deadly virus.

Nipah virus (NiV) antiviral therapies monoclonal antibodies vaccine development preventive measures

References (37)

  1. 1 Clinical Features of Nipah Virus Encephalitis among Pig Farmers in Malaysia [DOI]
  2. 2 Outbreak of Nipah-virus infection among abattoir workers in Singapore [DOI]
  3. 3 Transmission of Human Infection with Nipah Virus [DOI]
  4. 4 Nipah virus: epidemiology, pathology, immunobiology and advances in diagnosis, vaccine designing and control strategies – a comprehensive review [DOI]
  5. 5 Clinical Presentation of Nipah Virus Infection in Bangladesh [DOI]
  6. 6 Treatment of acute Nipah encephalitis with ribavirin [DOI]
  7. 7 Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge [DOI]
  8. 8 Nipah virus: Impact, origins, and causes of emergence [DOI]
  9. 9 Transmission of Nipah Virus — 14 Years of Investigations in Bangladesh [DOI]
  10. 10 Nipah virus infection: A review [DOI]
  11. 11 Exceptionally Potent Cross-Reactive Neutralization of Nipah and Hendra Viruses by a Human Monoclonal Antibody [DOI]
  12. 12 Favipiravir (T-705) protects against Nipah virus infection in the hamster model [DOI]
  13. 13 A Hendra Virus G Glycoprotein Subunit Vaccine Protects African Green Monkeys from Nipah Virus Challenge [DOI]
  14. 14 Combined chloroquine and ribavirin treatment does not prevent death in a hamster model of Nipah and Hendra virus infection [DOI]
  15. 15 Convergence of Humans, Bats, Trees, and Culture in Nipah Virus Transmission, Bangladesh [DOI]
  16. 16 Nano-based approach to combat emerging viral (NIPAH virus) infection [DOI]
  17. 17 An antibody against the F glycoprotein inhibits Nipah and Hendra virus infections [DOI]
  18. 18 Date Palm Sap Collection: Exploring Opportunities to Prevent Nipah Transmission [DOI]
  19. 19 Architecture and antigenicity of the Nipah virus attachment glycoprotein [DOI]
  20. 20 mRNA vaccines: The future of prevention of viral infections? [DOI]
  21. 21 Nipah Virus Disease: Recent Perspective and One Health Approach [DOI]
  22. 22 Nipah Virus: A Multidimensional Update [DOI]
  23. 23 Late remdesivir treatment initiation partially protects African green monkeys from lethal Nipah virus infection [DOI]
  24. 24 Inhibition of Nipah Virus Infection In Vivo: Targeting an Early Stage of Paramyxovirus Fusion Activation during Viral Entry [DOI]
  25. 25 Use of Infrared Camera to Understand Bats’ Access to Date Palm Sap: Implications for Preventing Nipah Virus Transmission [DOI]
  26. 26 Chloroquine Administration Does Not Prevent Nipah Virus Infection and Disease in Ferrets [DOI]
  27. 27 Transmission of henipaviruses [DOI]
  28. 28 Fusion Inhibitory Lipopeptides Engineered for Prophylaxis of Nipah Virus in Primates [DOI]
  29. 29 Advances in diagnostics, vaccines and therapeutics for Nipah virus [DOI]
  30. 30 Molecular epidemiology and phylogeny of Nipah virus infection: A mini review [DOI]
  31. 31 A Controlled Trial to Reduce the Risk of Human Nipah Virus Exposure in Bangladesh [DOI]
  32. 32 Screening and structure-based modeling of T-cell epitopes of Nipah virus proteome: an immunoinformatic approach for designing peptide-based vaccine [DOI]
  33. 33 Bacterial Metabarcoding of Raw Palm Sap Samples from Bangladesh with Nanopore Sequencing [DOI]
  34. 34 Controlling Nipah virus encephalitis in Bangladesh: Policy options [DOI]
  35. 35 Exposure-Based Screening for Nipah Virus Encephalitis, Bangladesh [DOI]
  36. 36 Low-Cost National Media-Based Surveillance System for Public Health Events, Bangladesh [DOI]
  37. 37 Recent Advances in Combating Nipah Virus Disease [DOI]

Cited by 6

Unraveling Nipah Virus: Key Insights on Spread, Symptoms, Management

Amit Kumar Kaundal, Inder Kumar, Kavita Pathania · Journal of Drug Delivery and Therapeutics · 2024

Nipah and chandipura viruses: Emerging neurotropic zoonotic viruses in south asia — a comparative review

Mustak Ahamed, Zuber Khan, Mumtaz · Molecular Biology Reports · 2026

Nipah Virus—Preparedness, Sustainability, and One Health Approaches for Monitoring and Control

Uzma Rahman, Mark Godfrey Joseph, Vikash Kumar · Health Information Science · 2026

Showing 3 of 6 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

45

Page views

0

PDF downloads

24

Outbound clicks

6

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.